NOVA1 acts as an oncogenic RNA-binding protein to regulate cholesterol homeostasis in human glioblastoma cells
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2314695121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Yuhki Saito und 6 weiteren Autor:innen. Beteiligte Einrichtung: HHMI, The Rockefeller University, New York, NY 10065. Hauptthemen laut MEDLINE: Glioblastoma, MicroRNAs. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, HHS | NIH | National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
NOVA1 is a neuronal RNA-binding protein identified as the target antigen of a rare autoimmune disorder associated with cancer and neurological symptoms, termed paraneoplastic opsoclonus-myoclonus ataxia. Despite the strong association between NOVA1 and cancer, it has been unclear how NOVA1 function might contribute to cancer biology. In this study, we find that NOVA1 acts as an oncogenic factor in a GBM (glioblastoma multiforme) cell line established from a patient. Interestingly, NOVA1 and Argonaute (AGO) CLIP identified common 3′ untranslated region (UTR) targets, which were down-regulated in NOVA1 knockdown GBM cells, indicating a transcriptome-wide intersection of NOVA1 and AGO–microRNA (miRNA) targets regulation. NOVA1 binding to 3′UTR targets stabilized transcripts including those encoding cholesterol homeostasis related proteins. Selective inhibition of NOVA1–RNA interactions with antisense oligonucleotides disrupted GBM cancer cell fitness. The precision of our GBM CLIP studies point to both mechanism and precise RNA sequence sites to selectively inhibit oncogenic NOVA1–RNA interactions. Taken together, we find that NOVA1 is commonly overexpressed in GBM, where it can antagonize AGO2–miRNA actions and consequently up-regulates cholesterol synthesis, promoting cell viability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HHMI, The Rockefeller University, New York, NY 10065.
- Laboratory of Molecular Neuro-oncology, The Rockefeller University, New York, NY 10065.
- Department of Neurosurgery, Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
- Cancer Biology and Genetics, Sloan Kettering Institute, New York, NY 10065.
ORCID-Profile: Robert B Darnell
Förderung
- NCI NIH HHS
- NINDS NIH HHS
- HHS | NIH | National Institute of Neurological Disorders and Stroke
- Starr Foundation
- Howard Hughes Medical Institute
Zitieren
APA
Saito, Y., Yang, Y., Saito, M., Park, C. Y., Funato, K., Tabar, V., & Darnell, R. B. (2024). NOVA1 acts as an oncogenic RNA-binding protein to regulate cholesterol homeostasis in human glioblastoma cells. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2314695121
Vancouver
Saito Y, Yang Y, Saito M, Park CY, Funato K, Tabar V, et al. NOVA1 acts as an oncogenic RNA-binding protein to regulate cholesterol homeostasis in human glioblastoma cells. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2314695121
BibTeX
@article{Saito2024,
author = {Saito, Yuhki and Yang, Yanhong and Saito, Misa and Park, Christopher Y and Funato, Kosuke and Tabar, Viviane and Darnell, Robert B},
title = {NOVA1 acts as an oncogenic RNA-binding protein to regulate cholesterol homeostasis in human glioblastoma cells},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2314695121}
}
EUVIMED